LIGAND PHARMACEUTICALS INC's ticker is LGND and the CUSIP is 53220K504. A total of 210 filers reported holding LIGAND PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.15 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $71 | +82.1% | 1,185 | +117.8% | 0.00% | – |
| Q2 2023 | $39 | -92.0% | 544 | -92.5% | 0.00% | -100.0% |
| Q4 2022 | $485 | -99.9% | 7,269 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $625,000 | +691.1% | 7,269 | +720.4% | 0.00% | – |
| Q2 2022 | $79,000 | -20.2% | 886 | 0.0% | 0.00% | – |
| Q1 2022 | $99,000 | -25.6% | 886 | +2.2% | 0.00% | – |
| Q4 2021 | $133,000 | +19.8% | 867 | +8.1% | 0.00% | – |
| Q3 2021 | $111,000 | -2.6% | 802 | -8.2% | 0.00% | – |
| Q2 2021 | $114,000 | -13.0% | 874 | +1.2% | 0.00% | – |
| Q1 2021 | $131,000 | +54.1% | 864 | 0.0% | 0.00% | – |
| Q4 2020 | $85,000 | -84.3% | 864 | -84.1% | 0.00% | -100.0% |
| Q3 2019 | $542,000 | +110.1% | 5,449 | +140.9% | 0.00% | – |
| Q2 2019 | $258,000 | -42.5% | 2,262 | -36.7% | 0.00% | -100.0% |
| Q1 2019 | $449,000 | +218.4% | 3,576 | +243.5% | 0.00% | – |
| Q4 2018 | $141,000 | -83.7% | 1,041 | -94.4% | 0.00% | -100.0% |
| Q3 2014 | $867,000 | – | 18,455 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knott David M Jr | 115,000 | $7,682 | 2.90% |
| VILLERE ST DENIS J & CO LLC | 483,347 | $32,287 | 2.52% |
| Monarch Partners Asset Management LLC | 62,327 | $4,163,444 | 1.23% |
| Chicago Capital, LLC | 319,054 | $21,312,820 | 1.18% |
| RICE HALL JAMES & ASSOCIATES, LLC | 285,634 | $19,080,351 | 1.09% |
| Stephens Investment Management Group LLC | 454,416 | $30,713,977 | 0.56% |
| Smith, Graham & Co., Investment Advisors, LP | 65,372 | $4,366,850 | 0.53% |
| WOODSTOCK CORP | 55,014 | $3,674,935 | 0.49% |
| Court Place Advisors, LLC | 15,533 | $1,037,605 | 0.38% |
| ISTHMUS PARTNERS, LLC | 19,830 | $1,324,644 | 0.20% |